PT  - JOURNAL ARTICLE
AU  - HEIKE, YUJI
AU  - HOSOKAWA, MAMI
AU  - OSUMI, SHOZO
AU  - FUJII, DAISUKE
AU  - AOGI, KENJIRO
AU  - TAKIGAWA, NAGIO
AU  - IDA, MIKIKO
AU  - TAJIRI, HISAO
AU  - EGUCHI, KENJI
AU  - SHIWA, MIEKO
AU  - WAKATABE, RUMI
AU  - ARIKUNI, HISASHI
AU  - TAKAUE, YOICHI
AU  - TAKASHIMA, SHIGEMITSU
TI  - Identification of Serum Proteins Related to Adverse Effects Induced by Docetaxel Infusion from Protein Expression Profiles of Serum Using SELDI ProteinChip System
DP  - 2005 Mar 01
TA  - Anticancer Research
PG  - 1197--1203
VI  - 25
IP  - 2B
4099  - http://ar.iiarjournals.org/content/25/2B/1197.short
4100  - http://ar.iiarjournals.org/content/25/2B/1197.full
SO  - Anticancer Res2005 Mar 01; 25
AB  - Background: For the development of quick and easy methods for screening and identifying treatment-responsive proteins, we determined the protein expression profile of the serum after docetaxel infusion using a surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI TOF-MS) system. Materials and Methods: Blood from breast cancer patients was collected before and 4, 8, 24 and 48 hours after docetaxel infusion. The protein expression profile was determined by a SELDI TOF-MS system. The relative expression levels of target proteins were compared during the time-course after docetaxel injection. Results: We identified two representative proteins with molecular weights of 7790 Da and 9285 Da. The 7790 Da protein was high molecular weight kininogen, and the 9285 Da protein was apolipoprotein A-II. These two proteins had similar expression patterns in 5 patients, except one patient who experienced severe, acute, adverse effects. Conclusion: These results suggest that protein expression profiles determined by SELDI TOF-MS represent useful data for the identification of treatment-responsive proteins. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved